Oramed’s Oravax Medical and Genomma Lab Internacional announce joint venture to develop and commercialize vaccine for Latin America.

Current Covid-19 vaccines are delivered via a shot in the arm – nobody’s favorite way to receive any medication – and must be kept at ultracold temperatures.

Oravax Medical, a subsidiary of Israel’s Oramed Pharmaceuticals, has a vaccine candidate that is given by mouth and doesn’t require freezer storage.

On November 18, Oravax announced a partnership with Genomma Lab Internacional www.genommalab.com/en/ in Mexico to develop the vaccine for use in Latin America initially.

Picture: Genomma Lab Chairman Rodrigo Herrera shakes on the vaccine development deal with Nadav Kidron, CEO of Oramed Pharmaceuticals and chairman of Oravax Medical. Photo by Daniela Blanco